Published in Clin Cancer Res on February 17, 2009
Epigenetic modifications as therapeutic targets. Nat Biotechnol (2010) 3.16
Epigenome-wide DNA methylation landscape of melanoma progression to brain metastasis reveals aberrations on homeobox D cluster associated with prognosis. Hum Mol Genet (2013) 1.95
Molecular pathological epidemiology of epigenetics: emerging integrative science to analyze environment, host, and disease. Mod Pathol (2013) 1.95
Downregulation of microRNA-29c is associated with hypermethylation of tumor-related genes and disease outcome in cutaneous melanoma. Epigenetics (2011) 1.55
RASSF1A-LATS1 signalling stabilizes replication forks by restricting CDK2-mediated phosphorylation of BRCA2. Nat Cell Biol (2014) 1.53
Epigenomic analysis of aberrantly methylated genes in colorectal cancer identifies genes commonly affected by epigenetic alterations. Ann Surg Oncol (2011) 1.50
Array-based DNA methylation profiling for breast cancer subtype discrimination. PLoS One (2010) 1.26
Epigenetics of human cutaneous melanoma: setting the stage for new therapeutic strategies. J Transl Med (2010) 1.17
SOCS, inflammation, and cancer. JAKSTAT (2013) 1.13
DNA methylation and gene deletion analysis of brain metastases in melanoma patients identifies mutually exclusive molecular alterations. Neuro Oncol (2014) 1.10
AIM1 and LINE-1 epigenetic aberrations in tumor and serum relate to melanoma progression and disease outcome. J Invest Dermatol (2012) 1.09
The prognostic role of RASSF1A promoter methylation in breast cancer: a meta-analysis of published data. PLoS One (2012) 1.08
DNA-methylation profiling distinguishes malignant melanomas from benign nevi. Pigment Cell Melanoma Res (2011) 1.08
Aberrant DNA methylation in malignant melanoma. Melanoma Res (2010) 1.04
Epigenetic status of LINE-1 predicts clinical outcome in early-stage rectal cancer. Br J Cancer (2013) 1.01
CpG island methylator phenotype-positive tumors in the absence of MLH1 methylation constitute a distinct subset of duodenal adenocarcinomas and are associated with poor prognosis. Clin Cancer Res (2012) 1.00
Whole genome methylation profiles as independent markers of survival in stage IIIC melanoma patients. J Transl Med (2012) 0.99
Methylation levels of the "long interspersed nucleotide element-1" repetitive sequences predict survival of melanoma patients. J Transl Med (2011) 0.99
Epigenetic regulation in human melanoma: past and future. Epigenetics (2015) 0.98
Dissecting DNA hypermethylation in cancer. FEBS Lett (2010) 0.98
Multiparametric analysis of cell-free DNA in melanoma patients. PLoS One (2012) 0.97
MiR-199a inhibits the ability of proliferation and migration by regulating CD44-Ezrin signaling in cutaneous squamous cell carcinoma cells. Int J Clin Exp Pathol (2014) 0.95
Heterogeneous epigenetic regulation of TIMP3 in prostate cancer. Epigenetics (2012) 0.94
Brain metastasis is predetermined in early stages of cutaneous melanoma by CD44v6 expression through epigenetic regulation of the spliceosome. Pigment Cell Melanoma Res (2014) 0.93
DNA methylation profiling in Barrett's esophagus and esophageal adenocarcinoma reveals unique methylation signatures and molecular subclasses. Epigenetics (2011) 0.93
KIT is a frequent target for epigenetic silencing in cutaneous melanoma. J Invest Dermatol (2014) 0.91
Integrating the multiple dimensions of genomic and epigenomic landscapes of cancer. Cancer Metastasis Rev (2010) 0.90
Melanoma epigenetics: novel mechanisms, markers, and medicines. Lab Invest (2014) 0.89
Clinical utility of RASSF1A methylation in human malignancies. Br J Cancer (2015) 0.89
RASSF1A suppresses melanoma development by modulating apoptosis and cell-cycle progression. J Cell Physiol (2011) 0.89
Application of biomarkers in cancer risk management: evaluation from stochastic clonal evolutionary and dynamic system optimization points of view. PLoS Comput Biol (2011) 0.89
Genome-Wide DNA Methylation Analysis in Melanoma Reveals the Importance of CpG Methylation in MITF Regulation. J Invest Dermatol (2015) 0.88
Assessment of DNA methylation status in early stages of breast cancer development. Br J Cancer (2013) 0.88
The association of RAS association domain family Protein1A (RASSF1A) methylation states and bladder cancer risk: a systematic review and meta-analysis. PLoS One (2012) 0.88
Progression of cutaneous melanoma: implications for treatment. Clin Exp Metastasis (2012) 0.87
CpG island methylator phenotype in plasma is associated with hepatocellular carcinoma prognosis. World J Gastroenterol (2011) 0.85
Unraveling breast cancer heterogeneity through transcriptomic and epigenomic analysis. Ann Surg Oncol (2009) 0.85
Epigenetic biomarkers in skin cancer. Cancer Lett (2012) 0.84
Predictive value of CpG island methylator phenotype for tumor recurrence in hepatitis B virus-associated hepatocellular carcinoma following liver transplantation. BMC Cancer (2010) 0.83
Prognostic molecular biomarkers for cutaneous malignant melanoma. J Surg Oncol (2011) 0.82
RASSF8 regulates progression of cutaneous melanoma through nuclear factor-κb. Oncotarget (2015) 0.81
Epigenetics of regional lymph node metastasis in solid tumors. Clin Exp Metastasis (2012) 0.81
Development of sporadic microsatellite instability in colorectal tumors involves hypermethylation at methylated-in-tumor loci in adenoma. Am J Pathol (2010) 0.81
DNA methylation profiles in primary cutaneous melanomas are associated with clinically significant pathologic features. Pigment Cell Melanoma Res (2014) 0.81
Biomarkers as key contributors in treating malignant melanoma metastases. Dermatol Res Pract (2011) 0.79
Epigenetic cancer prevention mechanisms in skin cancer. AAPS J (2013) 0.79
Analysis of the molecular features of rectal carcinoid tumors to identify new biomarkers that predict biological malignancy. Oncotarget (2015) 0.78
Epigenetic regulation of REG1A and chemosensitivity of cutaneous melanoma. Epigenetics (2013) 0.78
Tumor-Related Methylated Cell-Free DNA and Circulating Tumor Cells in Melanoma. Front Mol Biosci (2016) 0.78
DNA Methylation Levels of Melanoma Risk Genes Are Associated with Clinical Characteristics of Melanoma Patients. Biomed Res Int (2015) 0.77
Emerging technologies for studying DNA methylation for the molecular diagnosis of cancer. Expert Rev Mol Diagn (2015) 0.77
Tumor necrosis factor-α and apoptosis induction in melanoma cells through histone modification by 3-deazaneplanocin A. J Invest Dermatol (2013) 0.77
Protein signatures correspond to survival outcomes of AJCC stage III melanoma patients. Pigment Cell Melanoma Res (2014) 0.77
DNA methylation subgroups in melanoma are associated with proliferative and immunological processes. BMC Med Genomics (2015) 0.75
Aberrant hypermethylation in primary tumours and sentinel lymph node metastases in paediatric patients with cutaneous melanoma. Br J Dermatol (2012) 0.75
A Systematic Analysis of the Relationship of CDH13 Promoter Methylation and Breast Cancer Risk and Prognosis. PLoS One (2016) 0.75
The relationship between RASSF1A gene promoter methylation and the susceptibility and prognosis of melanoma: A meta-analysis and bioinformatics. PLoS One (2017) 0.75
miR-199a-5p induces cell invasion by suppressing E-cadherin expression in cutaneous squamous cell carcinoma. Oncol Lett (2016) 0.75
The Emergence of Pan-Cancer CIMP and Its Elusive Interpretation. Biomolecules (2016) 0.75
Epigenetic alterations in metastatic cutaneous carcinoma. Head Neck (2014) 0.75
Aberrant DNA methylation in melanoma: biomarker and therapeutic opportunities. Clin Epigenetics (2017) 0.75
Epigenetic Regulation of KPC1 Ubiquitin Ligase Effects the NF-κB Pathway in Melanoma. Clin Cancer Res (2017) 0.75
Down-regulation of MFG-E8 by RNA interference combined with doxorubicin triggers melanoma destruction. Clin Exp Med (2014) 0.75
Cancer statistics, 2007. CA Cancer J Clin (2007) 53.49
Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med (2003) 18.04
MethPrimer: designing primers for methylation PCRs. Bioinformatics (2002) 14.48
CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A (1999) 13.02
Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol (2001) 9.68
CpG island methylator phenotype is an independent predictor of survival benefit from 5-fluorouracil in stage III colorectal cancer. Clin Cancer Res (2003) 2.48
GATA-4 and GATA-5 transcription factor genes and potential downstream antitumor target genes are epigenetically silenced in colorectal and gastric cancer. Mol Cell Biol (2003) 2.42
Wnt inhibitory factor-1 is silenced by promoter hypermethylation in human lung cancer. Cancer Res (2004) 2.09
Frequent epigenetic inactivation of Wnt inhibitory factor-1 in human gastrointestinal cancers. Oncogene (2005) 1.82
Profiling epigenetic inactivation of tumor suppressor genes in tumors and plasma from cutaneous melanoma patients. Oncogene (2004) 1.81
Epigenetic inactivation of Wnt inhibitory factor-1 plays an important role in bladder cancer through aberrant canonical Wnt/beta-catenin signaling pathway. Clin Cancer Res (2006) 1.73
Epigenetic inactivation of RAS association domain family protein 1 (RASSF1A) in malignant cutaneous melanoma. Cancer Res (2003) 1.48
Hypermethylation of the GATA genes in lung cancer. Clin Cancer Res (2004) 1.45
Wnt antagonist family genes as biomarkers for diagnosis, staging, and prognosis of renal cell carcinoma using tumor and serum DNA. Clin Cancer Res (2006) 1.41
Predictive utility of circulating methylated DNA in serum of melanoma patients receiving biochemotherapy. J Clin Oncol (2005) 1.40
Genetic, epigenetic, and clinicopathologic features of gastric carcinomas with the CpG island methylator phenotype and an association with Epstein-Barr virus. Cancer (2006) 1.37
Synthesis of universal unmethylated control DNA by nested whole genome amplification with phi29 DNA polymerase. Biochem Biophys Res Commun (2005) 1.26
Silencing of tissue factor pathway inhibitor-2 gene in malignant melanomas. Int J Cancer (2007) 1.21
Epigenetic inactivation of tumor suppressor genes in serum of patients with cutaneous melanoma. J Invest Dermatol (2006) 1.13
The role of tissue factor pathway inhibitor-2 in cancer biology. Semin Thromb Hemost (2007) 1.10
Assessment of methylation events during colorectal tumor progression by absolute quantitative analysis of methylated alleles. Mol Cancer Res (2007) 1.05
Wnt inhibitory factor-1 gene transfer inhibits melanoma cell growth. Hum Gene Ther (2007) 1.02
Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol (2009) 23.08
A landscape of driver mutations in melanoma. Cell (2012) 12.61
Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer (2011) 7.69
Sentinel node biopsy and standard of care for melanoma. J Am Acad Dermatol (2009) 4.32
Impact of micrometastases in the sentinel node of patients with invasive breast cancer. J Clin Oncol (2009) 3.36
Activation of CCR9/CCL25 in cutaneous melanoma mediates preferential metastasis to the small intestine. Clin Cancer Res (2008) 3.24
The impact on morbidity and length of stay of early versus delayed complete lymphadenectomy in melanoma: results of the Multicenter Selective Lymphadenectomy Trial (I). Ann Surg Oncol (2010) 3.02
Improved survival after lymphadenectomy for nodal metastasis from an unknown primary melanoma. J Clin Oncol (2008) 2.53
Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival. J Clin Oncol (2005) 2.41
Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol (2010) 2.30
Prognostic impact of micrometastases in colon cancer: interim results of a prospective multicenter trial. Ann Surg (2007) 2.28
An evidence-based staging system for cutaneous melanoma. CA Cancer J Clin (2004) 2.18
Incidence of BRAF oncogene mutation and clinical relevance for primary cutaneous melanomas. Clin Cancer Res (2004) 2.05
Direct serum assay for microRNA-21 concentrations in early and advanced breast cancer. Clin Chem (2010) 2.03
Melanoma patients with positive sentinel nodes who did not undergo completion lymphadenectomy: a multi-institutional study. Ann Surg Oncol (2006) 2.00
Epigenetic silencing of cyclooxygenase-2 affects clinical outcome in gastric cancer. J Clin Oncol (2007) 1.97
Epigenome-wide DNA methylation landscape of melanoma progression to brain metastasis reveals aberrations on homeobox D cluster associated with prognosis. Hum Mol Genet (2013) 1.95
Metastasectomy for distant metastatic melanoma: analysis of data from the first Multicenter Selective Lymphadenectomy Trial (MSLT-I). Ann Surg Oncol (2012) 1.92
Profiling epigenetic inactivation of tumor suppressor genes in tumors and plasma from cutaneous melanoma patients. Oncogene (2004) 1.81
Prolonged survival after complete resection of metastases from intraocular melanoma. Cancer (2004) 1.78
Prediction of disease outcome in melanoma patients by molecular analysis of paraffin-embedded sentinel lymph nodes. J Clin Oncol (2003) 1.78
Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database. J Clin Oncol (2011) 1.78
FOXC1 is a potential prognostic biomarker with functional significance in basal-like breast cancer. Cancer Res (2010) 1.73
Prediction of breast tumor progression by integrity of free circulating DNA in serum. J Clin Oncol (2006) 1.73
c-MET expression level in primary colon cancer: a predictor of tumor invasion and lymph node metastases. Clin Cancer Res (2003) 1.73
Microphthalmia transcription factor as a molecular marker for circulating tumor cell detection in blood of melanoma patients. Clin Cancer Res (2006) 1.72
BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition. Proc Natl Acad Sci U S A (2013) 1.72
Distinct hypermethylation profile of primary breast cancer is associated with sentinel lymph node metastasis. Clin Cancer Res (2005) 1.70
LINE-1 hypomethylation during primary colon cancer progression. PLoS One (2011) 1.66
Prognostic implications of thick (>or=4-mm) melanoma in the era of intraoperative lymphatic mapping and sentinel lymphadenectomy. Ann Surg Oncol (2002) 1.65
S1PR1-STAT3 signaling is crucial for myeloid cell colonization at future metastatic sites. Cancer Cell (2012) 1.64
Cancer Cells Expressing Toll-like Receptors and the Tumor Microenvironment. Cancer Microenviron (2009) 1.60
Increased integrity of free circulating DNA in sera of patients with colorectal or periampullary cancer: direct quantitative PCR for ALU repeats. Clin Chem (2006) 1.58
Downregulation of microRNA-29c is associated with hypermethylation of tumor-related genes and disease outcome in cutaneous melanoma. Epigenetics (2011) 1.55
Staging of regional lymph nodes in melanoma: a case for including nonsentinel lymph node positivity in the American Joint Committee on Cancer staging system. JAMA Surg (2013) 1.52
Contemporary surgical treatment of advanced-stage melanoma. Arch Surg (2004) 1.52
Prognostic significance of molecular upstaging of paraffin-embedded sentinel lymph nodes in melanoma patients. J Clin Oncol (2004) 1.50
CCL21 chemokine regulates chemokine receptor CCR7 bearing malignant melanoma cells. Clin Cancer Res (2004) 1.50
Epigenetic inactivation of RAS association domain family protein 1 (RASSF1A) in malignant cutaneous melanoma. Cancer Res (2003) 1.48
A collagen-remodeling gene signature regulated by TGF-β signaling is associated with metastasis and poor survival in serous ovarian cancer. Clin Cancer Res (2013) 1.46
Peripheral blood CD4+ T-cell response before postoperative active immunotherapy correlates with clinical outcome in metastatic melanoma. Ann Surg Oncol (2004) 1.44
Serum anti-ganglioside IgM antibodies in soft tissue sarcoma: clinical prognostic implications. Cancer J (2002) 1.43
Systemic irinotecan and regional floxuridine after hepatic cytoreduction in 185 patients with unresectable colorectal cancer metastases. Ann Surg Oncol (2002) 1.42
Preoperative imaging of pulmonary metastases in patients with melanoma: implications for minimally invasive techniques. Arch Surg (2012) 1.41
Predictive utility of circulating methylated DNA in serum of melanoma patients receiving biochemotherapy. J Clin Oncol (2005) 1.40
Serum TA90 immune complex assay can predict outcome after resection of thick (> or =4 mm) primary melanoma and sentinel lymphadenectomy. Ann Surg Oncol (2002) 1.39
Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine. J Clin Oncol (2002) 1.38
Serial monitoring of circulating melanoma cells during neoadjuvant biochemotherapy for stage III melanoma: outcome prediction in a multicenter trial. J Clin Oncol (2005) 1.37
New TNM melanoma staging system: linking biology and natural history to clinical outcomes. Semin Surg Oncol (2003) 1.34
Utility of circulating B-RAF DNA mutation in serum for monitoring melanoma patients receiving biochemotherapy. Clin Cancer Res (2007) 1.33
Association of circulating tumor cells with serum tumor-related methylated DNA in peripheral blood of melanoma patients. Cancer Res (2006) 1.32
Prediction of metastatic melanoma in nonsentinel nodes and clinical outcome based on the primary melanoma and the sentinel node. Mod Pathol (2004) 1.32
Authors' response to a letter to the editor re: Sentinel node biopsy for early-stage melanoma. Ann Surg (2007) 1.32
Chemokine receptor CXCR4 expression in patients with melanoma and colorectal cancer liver metastases and the association with disease outcome. Ann Surg (2006) 1.31
AJCC Cancer Staging Manual 7th edition criteria for colon cancer: do the complex modifications improve prognostic assessment? J Am Coll Surg (2013) 1.31
Does metastasectomy improve survival in patients with Stage IV melanoma? A cancer registry analysis of outcomes. J Surg Oncol (2011) 1.29
Prospective multicenter trial of staging adequacy in colon cancer: preliminary results. Arch Surg (2006) 1.28
Synthesis of universal unmethylated control DNA by nested whole genome amplification with phi29 DNA polymerase. Biochem Biophys Res Commun (2005) 1.26
Acetylated STAT3 is crucial for methylation of tumor-suppressor gene promoters and inhibition by resveratrol results in demethylation. Proc Natl Acad Sci U S A (2012) 1.26
Enhanced survival associated with vitiligo expression during maintenance biotherapy for metastatic melanoma. J Invest Dermatol (2006) 1.26
Practice patterns and outcomes for anorectal melanoma in the USA, reviewing three decades of treatment: is more extensive surgical resection beneficial in all patients? Ann Surg Oncol (2009) 1.25
Epigenetic inactivation of ID4 in colorectal carcinomas correlates with poor differentiation and unfavorable prognosis. Clin Cancer Res (2004) 1.25
Multimarker quantitative real-time PCR detection of circulating melanoma cells in peripheral blood: relation to disease stage in melanoma patients. Clin Chem (2005) 1.25
Aberrant hypermethylation of ID4 gene promoter region increases risk of lymph node metastasis in T1 breast cancer. Oncogene (2005) 1.24
Expression of differentiation melanoma-associated antigen genes is associated with favorable disease outcome in advanced-stage melanomas. Cancer Res (2003) 1.24
Endogenous immune response to gangliosides in patients with confined prostate cancer. Int J Cancer (2005) 1.23
Activation of Toll-like receptors 2, 3, and 4 on human melanoma cells induces inflammatory factors. Mol Cancer Ther (2008) 1.23
Age-related lymphatic dysfunction in melanoma patients. Ann Surg Oncol (2009) 1.22
The role of fluorine-18 deoxyglucose positron emission tomography in the management of patients with metastatic melanoma: impact on surgical decision making. Clin Nucl Med (2003) 1.21
Estrogen receptor and HER2/neu status affect epigenetic differences of tumor-related genes in primary breast tumors. Breast Cancer Res (2008) 1.20
Factors predictive of tumor-positive nonsentinel lymph nodes after tumor-positive sentinel lymph node dissection for melanoma. J Clin Oncol (2004) 1.20
Serial monitoring of circulating tumor cells predicts outcome of induction biochemotherapy plus maintenance biotherapy for metastatic melanoma. Clin Cancer Res (2010) 1.19
Isolated tumor cells in the sentinel node affect long-term prognosis of patients with melanoma. Ann Surg Oncol (2007) 1.19
Peptide nucleic acid clamp PCR: a novel K-ras mutation detection assay for colorectal cancer micrometastases in lymph nodes. Int J Cancer (2004) 1.19
Detection of circulating tumor cells in early-stage breast cancer metastasis to axillary lymph nodes. Clin Cancer Res (2007) 1.19
Quantification of circulating DNA in the plasma and serum of cancer patients. Ann N Y Acad Sci (2004) 1.18
Improved survival for stage IV melanoma from an unknown primary site. J Clin Oncol (2009) 1.18
Effect of lymphatic mapping on the new tumor-node-metastasis classification for colorectal cancer. J Clin Oncol (2003) 1.18
Late recurrence in melanoma: clinical implications of lost dormancy. J Am Coll Surg (2013) 1.18